First-Line Pembrolizumab Plus Chemotherapy for HER2-Negative Advanced Gastric Cancer: China Subgroup Analysis of the Randomized Phase 3 KEYNOTE-859 Study
First-Line Pembrolizumab Plus Chemotherapy for HER2-Negative Advanced Gastric Cancer: China Subgroup Analysis of the Randomized Phase 3 KEYNOTE-859 Study
Sonal Bordia, Shouguo Li, Yi Zuo, Hongming Pan et al.
Citations
4 citations
Journal
Advances in Therapy
Topics
Gastric Cancer Management and Outcomes
Field-Weighted Citation Impact (FWCI)
6.07
article
First-Line Pembrolizumab Plus Chemotherapy for HER2-Negative Advanced Gastric Cancer: China Subgroup Analysis of the Randomized Phase 3 KEYNOTE-859 Study
Sonal Bordia, Shouguo Li, Yi Zuo, Hongming Pan, Jieer Ying, Lin Yang, Xinjun Liang, Xiaoyan Lin, Shukui Qin, Yanli Qu, Jin Li, Yuxian Bai, Wěi Li, Xi Chen, Feng Ye, Suxia Luo, Tianshu Liu, Lin Zhao, Jianwei Yang, Yixiang Mao, Run Guo
article en
4 citations
Abstract
No abstract available for this paper.
Publication Tag
Advances in TherapyVol. 42(4)
Institutions
Merck & Co., Inc., Rahway, NJ, USA (United States) (US), Fujian Medical University (CN), Xinjiang Medical University (CN), Harbin Medical University (CN), China Pharmaceutical University (CN), Jilin University (CN), Chinese Academy of Medical Sciences & Peking Union Medical College (CN), Fudan University (CN), Peking Union Medical College Hospital (CN), Sir Run Run Shaw Hospital (CN), Zhengzhou University (CN), First Affiliated Hospital of Xiamen University (CN), 117th Hospital of People's Liberation Army (CN), Zhejiang Cancer Hospital (CN), Third Affiliated Hospital of Harbin Medical University (CN), Zhongshan Hospital of Xiamen University (CN), First Hospital of Jilin University (CN), Zhongshan Hospital (CN), Shanghai East Hospital (CN), Henan Cancer Hospital (CN), Fujian Provincial Cancer Hospital (CN), Nanjing Jiangning Hospital (CN), Chinese People's Liberation Army (CN), Hubei Cancer Hospital (CN), PLA Army Engineering University (CN), Union Hospital (CN), Zhejiang University (CN)